CHM chimeric therapeutics limited

Ann: Dose finding complete in ADVENT-AML Phase 1b clinical trial, page-9

  1. 8,329 Posts.
    lightbulb Created with Sketch. 3661
    Yes, quite right. That's the trouble with having too many tabs open at the same time and so many CHM trials on the go! Thanks, again, reon.

    So, we have yet to receive any news regarding CORE-NK with Vactosertib for bowel cancer? But have the CR at 28-days in AML in combo with the other novel drugs.

    MDA are being tight-lipped with the ADVENT-AML progress (other than its safe to progress to the next stage). I guess they have nothing to gain by unveiling efficacy signals (if any) beyond what is expected for the SOC therapies.


 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
0.4¢
Change
0.000(0.00%)
Mkt cap ! $8.060M
Open High Low Value Volume
0.4¢ 0.4¢ 0.4¢ $100 25K

Buyers (Bids)

No. Vol. Price($)
28 21874000 0.4¢
 

Sellers (Offers)

Price($) Vol. No.
0.5¢ 19510638 27
View Market Depth
Last trade - 15.25pm 17/06/2025 (20 minute delay) ?
CHM (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.